METiS TechBio (7666.HK), a leading AI-powered drug delivery innovation company, today announced the localized deployment of its proprietary AiTEM AI Drug Formulation Platform at Hengrui Pharma (600276.SH; 01276.HK) to accelerate drug formulation development.
This collaboration marks the commercial deployment of the NanoForge-powered AiTEM AI Drug Formulation Platform beyond METiS TechBio and the beginning of NanoForge serving as the foundation for next-generation intelligent R&D infrastructure.
NanoForge is METiS TechBio's proprietary AI-powered nanodelivery platform and the world's first platform of its kind. It integrates the world's first AI-for-Nano de novo lipid generation algorithm, a proprietary lipid foundation model, METiS AI Agents, and a high-throughput closed-loop platform integrating dry-lab and wet-lab experimentation. NanoForge has become a critical AI for Science infrastructure for drug delivery..
As of May 2026, NanoForge has accumulated more than 10 million lipid structures and over 100,000 experimental data points, enabling METiS TechBio's R&D team to advance more than 10 first-in-class or best-in-class programs while achieving breakthrough targeted delivery across eight major human organs and tissues.
Powered by NanoForge, METiS TechBio's proprietary AI-powered nanodelivery platform, AiTEM leverages proprietary algorithms to design and optimize drug formulations. Through quantum chemistry and molecular dynamics simulations, the platform predicts interactions between drug molecules and excipients and generates optimized drug formulation solutions across multiple dosage forms to improve drug solubility, permeability, and bioavailability while achieving desirable pharmacokinetic profiles.
In MTS-004, China's first AI-powered formulation drug candidate to complete Phase III clinical trials, AiTEM was responsible for formulation modeling and predictive analysis, shortening the preclinical drug formulation optimization cycle from the industry average of 1 to 2 years to less than 3 months. MTS-004 progressed from project initiation to completion of Phase III clinical trials in just 38 months, significantly accelerating drug development compared with the industry average.
Dr. Chris Lai, Co-founder, Chairman and Chief Executive Officer of METiS TechBio, said:
"Hengrui Pharma is one of China's leading innovative pharmaceutical companies. We look forward to working closely with Hengrui Pharmato accelerate the integration of artificial intelligence into the life sciences. Artificial intelligence is fundamentally reshaping the R&D paradigm in the life sciences, and NanoForge is evolving into a next-generation R&D infrastructure that will support continuous innovation across the life sciences."
